دورية أكاديمية
أعرض في EDS

Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures.

التفاصيل البيبلوغرافية
العنوان: Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures.
المؤلفون: Farhoumand LS; Eye Research Lab, Department of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Liu H; Eye Research Lab, Department of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Tsimpaki T; Eye Research Lab, Department of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Hendgen-Cotta UB; CardioScience Labs, Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Rassaf T; CardioScience Labs, Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Bechrakis NE; Eye Research Lab, Department of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Fiorentzis M; Eye Research Lab, Department of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Berchner-Pfannschmidt U; Eye Research Lab, Department of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2023 Mar 20; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Ethanolamines*/pharmacology , Melanoma*/drug therapy, Adult ; Humans ; Nebivolol/pharmacology ; Benzopyrans/pharmacology ; Adrenergic beta-Antagonists/pharmacology ; Receptors, Adrenergic, beta
مستخلص: Uveal melanoma (UM) is the most common primary cancer of the eye in adults. A new systemic therapy is needed to reduce the high metastasis and mortality rate. As β-blockers are known to have anti-tumor effects on various cancer entities, this study focuses on investigating the effect of β1-selective blockers atenolol, celiprolol, bisoprolol, metoprolol, esmolol, betaxolol, and in particular, nebivolol on UM. The study was performed on 3D tumor spheroids as well as 2D cell cultures, testing tumor viability, morphological changes, long-term survival, and apoptosis. Flow cytometry revealed the presence of all three β-adrenoceptors with a dominance of β2-receptors on cell surfaces. Among the blockers tested, solely nebivolol concentration-dependently decreased viability and altered 3D tumor spheroid structure. Nebivolol blocked the repopulation of cells spreading from 3D tumor spheroids, indicating a tumor control potential at a concentration of ≥20 µM. Mechanistically, nebivolol induced ATP depletion and caspase-3/7 activity, indicating that mitochondria-dependent signaling is involved. D-nebivolol or nebivolol combined with the β2-antagonist ICI 118.551 displayed the highest anti-tumor effects, suggesting a contribution of both β1- and β2-receptors. Thus, the present study reveals the tumor control potential of nebivolol in UM, which may offer a perspective for co-adjuvant therapy to reduce recurrence or metastasis.
References: Respiration. 2004 Mar-Apr;71(2):159-64. (PMID: 15031571)
Front Pharmacol. 2022 Dec 06;13:1049640. (PMID: 36561339)
Curr Hypertens Rev. 2019;15(1):22-31. (PMID: 30227820)
Int J Cancer. 1997 Nov 14;73(4):470-8. (PMID: 9389558)
Rev Esp Cardiol (Engl Ed). 2019 Oct;72(10):853-862. (PMID: 31178382)
Semin Cancer Biol. 2013 Dec;23(6 Pt B):533-42. (PMID: 24012659)
Cancer Med. 2019 Dec;8(17):7265-7277. (PMID: 31588689)
Trans Am Ophthalmol Soc. 2016 Aug;114:T5. (PMID: 28018010)
Pharmaceutics. 2021 Dec 22;14(1):. (PMID: 35056909)
BMC Cell Biol. 2013 Jul 09;14:32. (PMID: 23834359)
Diagn Cytopathol. 2016 May;44(5):377-83. (PMID: 26876235)
Cancers (Basel). 2019 Jun 19;11(6):. (PMID: 31248118)
Cancers (Basel). 2021 Nov 13;13(22):. (PMID: 34830841)
N Engl J Med. 2010 Dec 2;363(23):2191-9. (PMID: 21083380)
Biotechnol J. 2008 Oct;3(9-10):1172-84. (PMID: 18566957)
Expert Rev Cardiovasc Ther. 2008 Apr;6(4):471-9. (PMID: 18402537)
J Cardiovasc Pharmacol. 1988 May;11(5):552-63. (PMID: 2455841)
Lancet. 1996 May 4;347(9010):1222-5. (PMID: 8622452)
Nat Commun. 2021 Oct 11;12(1):5919. (PMID: 34635651)
Cancers (Basel). 2022 Jun 23;14(13):. (PMID: 35804869)
Dermatol Online J. 2015 Jul 15;21(7):. (PMID: 26436966)
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4660-4. (PMID: 14578382)
Nat Commun. 2020 Jul 17;11(1):3606. (PMID: 32681016)
Pharmacol Res. 2020 Jan;151:104587. (PMID: 31809852)
J Biomol Screen. 2004 Jun;9(4):273-85. (PMID: 15191644)
J Cell Biol. 1999 Jan 25;144(2):281-92. (PMID: 9922454)
Lancet. 1992 Mar 14;339(8794):691-2. (PMID: 1347396)
J Clin Hypertens (Greenwich). 2011 Sep;13(9):649-53. (PMID: 21896144)
Nat Rev Drug Discov. 2019 Jan;18(1):41-58. (PMID: 30310233)
Carbohydr Polym. 2016 Oct 5;150:139-48. (PMID: 27312623)
Drugs. 2015 Aug;75(12):1349-71. (PMID: 26177892)
Oncotarget. 2015 Feb 28;6(6):4266-73. (PMID: 25738355)
Front Pharmacol. 2021 Aug 12;12:691998. (PMID: 34456721)
Mol Oncol. 2014 Dec;8(8):1508-20. (PMID: 24994677)
Clin Cancer Res. 2012 Mar 1;18(5):1201-6. (PMID: 22186256)
Cancers (Basel). 2021 Jun 21;13(12):. (PMID: 34205625)
Biochemistry. 2021 Sep 21;60(37):2824-2835. (PMID: 34472839)
Asian Pac J Cancer Prev. 2022 May 01;23(5):1791-1801. (PMID: 35633566)
Eye (Lond). 2017 Feb;31(2):241-257. (PMID: 27911450)
Oncotarget. 2010 Nov;1(7):628-38. (PMID: 21317458)
Cardiovasc Ther. 2008 Summer;26(2):115-34. (PMID: 18485134)
Cancer. 2016 Aug 1;122(15):2299-312. (PMID: 26991400)
Prog Cardiovasc Dis. 2004 Jul-Aug;47(1):11-33. (PMID: 15517513)
Ophthalmologica. 2009;223(3):196-201. (PMID: 19212147)
Nat Rev Dis Primers. 2020 Apr 9;6(1):24. (PMID: 32273508)
Pigment Cell Melanoma Res. 2012 Mar;25(2):182-7. (PMID: 22236444)
Acta Ophthalmol. 2018 Feb;96(1):31-38. (PMID: 28444874)
Ther Adv Med Oncol. 2020 Oct 22;12:1758835920965852. (PMID: 33149769)
J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9. (PMID: 19815121)
Br J Pharmacol. 2019 Jul;176(14):2496-2508. (PMID: 30471093)
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9. (PMID: 14578381)
Curr Med Res Opin. 2010 Mar;26(3):615-29. (PMID: 20067434)
Int J Cancer. 1995 Jul 17;62(2):155-61. (PMID: 7622289)
Anticancer Res. 1998 Nov-Dec;18(6A):4147-58. (PMID: 9891460)
J Cardiovasc Pharmacol. 1991 Jun;17(6):964-9. (PMID: 1714022)
Cancer Gene Ther. 2022 Dec;29(12):1819-1826. (PMID: 35236928)
Mol Pharmacol. 1988 Dec;34(6):843-51. (PMID: 2462161)
Science. 2010 Dec 3;330(6009):1410-3. (PMID: 21051595)
Int J Mol Sci. 2021 Jun 23;22(13):. (PMID: 34201614)
Am J Health Syst Pharm. 2008 Feb 1;65(3):190. (PMID: 18215997)
معلومات مُعتمدة: ELAN 2023 Essen Laboratory and Science Training Program for Young Physicians; CSC 2023 Chinese Scholarship Fund
فهرسة مساهمة: Keywords: 3D tumor spheroids; anti-tumor activity; nebivolol; tumor control potential; uveal melanoma; ß1-selective blocker
المشرفين على المادة: 030Y90569U (Nebivolol)
0 (Ethanolamines)
0 (Benzopyrans)
0 (Adrenergic beta-Antagonists)
0 (Receptors, Adrenergic, beta)
SCR Disease Name: Uveal melanoma
تواريخ الأحداث: Date Created: 20230329 Date Completed: 20230330 Latest Revision: 20230331
رمز التحديث: 20230331
مُعرف محوري في PubMed: PMC10054088
DOI: 10.3390/ijms24065894
PMID: 36982966
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms24065894